Fortress Biotech Inc. (NASDAQ:FBIO) shares dropped 2.6% during trading on Tuesday . The company traded as low as $3.00 and last traded at $3.04, with a volume of 63,642 shares trading hands. The stock had previously closed at $3.12.

Separately, FBR & Co reissued an “outperform” rating and set a $7.00 price objective on shares of Fortress Biotech in a report on Wednesday, April 6th.

The company’s market cap is $147.98 million. The stock has a 50 day moving average price of $2.78 and a 200 day moving average price of $2.96.

Fortress Biotech (NASDAQ:FBIO) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter. Equities analysts expect that Fortress Biotech Inc. will post ($1.23) earnings per share for the current fiscal year.

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.